About
Dr William "Will" McEwan is a Cambridge-based neuroscientist and biotech academic founder focused on protein aggregation, intracellular immunity, and neurodegenerative disease. Public sources identify him as an academic co-founder of TRIMTECH Therapeutics and as a researcher at the UK Dementia Research Institute at the University of Cambridge. His work centers on mechanisms such as TRIM21-mediated degradation relevant to diseases including Alzheimer's, Huntington's, and Parkinson's.
Areas of interest
neurodegenerationbiotechprotein degradationtargeted protein degradationalzheimer's diseasehuntington's diseaseparkinson's diseaseintracellular immunityprotein aggregationdementia research